Add like
Add dislike
Add to saved papers

Efficacy and safety of loading doses with P2Y12-receptor antagonists in patients without dual antiplatelet therapy undergoing elective coronary intervention.

BACKGROUND: European Guidelines on Myocardial Revascularization recommend clopidogrel loading dose added to acetylsalicylic acid in elective percutaneous coronary interventions (PCI). However, there is few evidence supporting this recommendation and other P2Y12 inhibitors have not been tested in these patients.

PURPOSE: To evaluate the effectiveness and safety of different loading doses of clopidogrel and ticagrelor in patients without double antiplatelet therapy and stable coronary disease (SCAD) undergoing elective PCI.

METHODS: Retrospective study of 147 consecutive patients with SCAD undergoing elective PCI. Loading P2Y12 inhibitor doses evaluated were: clopidogrel 600 mg, clopidogrel 300 mg, clopidogrel 150 mg and ticagrelor 180 mg. We analyzed the occurrence of major adverse cardiovascular events (MACE) and periprocedural myocardial infarction (PMI).

RESULTS: 125 patients were treated with clopidogrel (16 with clopidogrel 150 mg, 7 with clopidogrel 300 mg, 93 with clopidogrel 600 mg) and 21 with ticagrelor 180 mg at the catheterization laboratory. Ticagrelor group had a significantly lower post-procedural peak of troponin-I (0.7±3.4 vs 0.3±0.7 ng/ml; p=0.02). There were no differences between groups in terms of major bleeding and hemoglobin drop post PCI (0.6±0.8 vs 4±0.6; p=0.8). The median of follow up was 17 months (interquartile range 9-32.7). At the end of follow up, MACE rate was not different between groups.

CONCLUSIONS: In patients without dual antiplatelet therapy undergoing elective PCI, the use of ticagrelor showed lower postprocedural myocardial injury without more bleeding complications.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app